Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'Donnell TF, Vora AN, Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MS.

J Am Coll Cardiol. 2014 Jun 10;63(22):2421-8. doi: 10.1016/j.jacc.2014.03.026. Epub 2014 Apr 9.

2.

Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.

Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald E.

Circulation. 2012 Jan 17;125(2):233-40. doi: 10.1161/CIRCULATIONAHA.111.063842. Epub 2011 Dec 16.

3.

Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.

Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J, Lemaire S, Kautzner J, Jarolim P.

JACC Heart Fail. 2015 Oct;3(10):829-39. doi: 10.1016/j.jchf.2015.05.012.

PMID:
26450001
4.

Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL; PEACE Trial Investigators.

N Engl J Med. 2004 Nov 11;351(20):2058-68. Epub 2004 Nov 7.

5.

Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.

Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E; Prevention of Events with ACE inhibition (PEACE) Investigators.

Circulation. 2006 Jul 4;114(1):26-31. Epub 2006 Jun 26.

6.

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.

Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators.

Circulation. 2007 Mar 27;115(12):1528-36. Epub 2007 Mar 19.

7.

Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.

Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E; PEACE Investigators.

J Am Coll Cardiol. 2007 Jul 17;50(3):205-14. Epub 2007 Jun 29.

8.

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC.

N Engl J Med. 1995 Dec 21;333(25):1670-6.

9.

Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.

O'Donoghue ML, Mallat Z, Morrow DA, Benessiano J, Sloan S, Omland T, Solomon SD, Braunwald E, Tedgui A, Sabatine MS.

Clin Chem. 2011 Sep;57(9):1311-7. doi: 10.1373/clinchem.2011.166520. Epub 2011 Jul 22.

10.
12.

Fibroblast growth factor-23 and cardiovascular events in CKD.

Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

J Am Soc Nephrol. 2014 Feb;25(2):349-60. doi: 10.1681/ASN.2013050465. Epub 2013 Oct 24.

13.

Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.

Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, Myers MG, Calciu CD, Dalle-Ave S, Martineau P, Mormont C, van Gilst WH; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators.

Circulation. 2008 Jan 1;117(1):24-31. Epub 2007 Dec 10.

14.

Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.

Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltytė Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald E; PEACE Investigators.

J Am Coll Cardiol. 2013 Mar 26;61(12):1240-9. doi: 10.1016/j.jacc.2012.12.026. Epub 2013 Feb 13. Erratum in: J Am Coll Cardiol. 2014 Jan 21;63(2):195-200.

16.

Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.

Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JA, Polak JF, Blondon M, Ruzinski J, Rock D, de Boer IH.

Circ Heart Fail. 2014 May;7(3):409-17. doi: 10.1161/CIRCHEARTFAILURE.113.000952. Epub 2014 Mar 25.

17.

Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.

Lewis EF, Solomon SD, Jablonski KA, Rice MM, Clemenza F, Hsia J, Maggioni AP, Zabalgoitia M, Huynh T, Cuddy TE, Gersh BJ, Rouleau J, Braunwald E, Pfeffer MA; PEACE Investigators.

Circ Heart Fail. 2009 May;2(3):209-16. doi: 10.1161/CIRCHEARTFAILURE.108.820696. Epub 2009 Apr 14.

18.

Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.

Torp-Pedersen C, Køber L, Carlsen J.

Am Heart J. 1996 Jul;132(1 Pt 2 Su):235-43.

PMID:
8677862
19.
20.

Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.

Humalda JK, Lambers Heerspink HJ, Kwakernaak AJ, Slagman MC, Waanders F, Vervloet MG, Ter Wee PM, Navis G, de Borst MH; NIGRAM Consortium.

Am J Kidney Dis. 2015 Feb;65(2):259-66. doi: 10.1053/j.ajkd.2014.07.022. Epub 2014 Sep 30.

PMID:
25278093

Supplemental Content

Support Center